Michail Maria, Birchwood Max, Tait Lynda
School of Health Sciences, Jubilee Campus, University of Nottingham, Nottingham NG7 2TU, UK.
Syst Rev. 2014 Jun 11;3:62. doi: 10.1186/2046-4053-3-62.
Social anxiety is among the most prevalent and debilitating affective disturbances manifest in people with psychosis. It is usually accompanied by high levels of depression and leads to significant social disability, lower quality of life and poorer prognosis as it raises the possibility of an early relapse. Despite its elevated prevalence and severity in psychosis, social anxiety remains under-recognized and under-treated. Cognitive-behavioural therapy is recommended for the treatment of people with psychosis. However, its focus and evaluation has primarily revolved around the reduction of psychotic symptoms, and not for co-morbid affective disturbances such as social anxiety. There is lack of evidence on the clinical effectiveness and cost-effectiveness of cognitive-behavioural interventions for the treatment of social anxiety disorder in psychosis.
METHODS/DESIGN: Electronic databases will be systematically searched for randomised controlled trials and quasi-experimental studies investigating the effectiveness and cost-effectiveness of cognitive-behavioural interventions for the treatment of social anxiety disorder in people with psychosis. Grey literature will also be searched by screening trial registers. Only studies published in English will be included in the review. Date restrictions will not be applied. Eligible studies will have as the primary outcome social anxiety (continuous data) measured using any psychometrically validated scale both self-reported and clinician administered. Secondary outcomes will include general anxiety symptoms, distress, depression, positive and negative symptoms of schizophrenia, and quality of life measured using any psychometrically validated scale, both self-reported and clinician administered, and the cost of cognitive-behaviour therapy (CBT) intervention (with another treatment or treatment-as-usual).
This review will provide an evidence synthesis of the effectiveness and cost-effectiveness of cognitive-behavioural interventions for the treatment of social anxiety disorder in people with psychosis. The review will identify the specific intervention components associated with effectiveness which will facilitate the translation of the existing evidence to the development of new, targeted interventions optimising these components. In doing so, this review will provide recommendations for the treatment of social anxiety and associated distress in psychosis and will further inform the development of future interventions in this area.
PROSPERO registration numberCRD42014009052.
社交焦虑是精神病患者中最普遍且使人衰弱的情感障碍之一。它通常伴有高度抑郁,会导致严重的社交功能丧失、生活质量下降以及预后较差,因为它增加了早期复发的可能性。尽管社交焦虑在精神病患者中患病率较高且症状严重,但仍未得到充分认识和治疗。认知行为疗法被推荐用于治疗精神病患者。然而,其重点和评估主要围绕减少精神病症状,而非针对社交焦虑等共病情感障碍。目前缺乏关于认知行为干预治疗精神病患者社交焦虑障碍的临床有效性和成本效益的证据。
方法/设计:将系统检索电子数据库,查找调查认知行为干预治疗精神病患者社交焦虑障碍有效性和成本效益的随机对照试验和准实验研究。还将通过筛选试验注册库来检索灰色文献。纳入综述的研究仅限英文发表。不设日期限制。符合条件的研究将以使用任何经心理测量学验证的自评和临床评定量表测量的社交焦虑(连续数据)作为主要结局。次要结局将包括一般焦虑症状、痛苦、抑郁、精神分裂症的阳性和阴性症状,以及使用任何经心理测量学验证的自评和临床评定量表测量的生活质量,以及认知行为疗法(CBT)干预的成本(与另一种治疗或常规治疗相比)。
本综述将提供认知行为干预治疗精神病患者社交焦虑障碍有效性和成本效益的证据综合。该综述将确定与有效性相关的具体干预成分,这将有助于将现有证据转化为优化这些成分的新的、有针对性的干预措施的开发。通过这样做,本综述将为治疗精神病患者的社交焦虑及相关痛苦提供建议,并将进一步为该领域未来干预措施的开发提供信息。
PROSPERO注册号CRD42014009052